title: Antiangiogenic therapy for high-grade gliomas: current concepts and limitations.
abstract: Glioblastoma (GBM) is associated with a high degree of angiogenesis. Therefore, antiangiogenic therapy could have a role in the treatment of this tumor. The currently available treatment approaches acting against angiogenesis are mainly directed toward three pathways: VEGF pathway, VEGF-independent pathways and inhibition of vascular endothelial cell migration. It has been demonstrated that antiangiogenic therapy can produce a rapid radiological response and a decrease of brain edema, without significantly influencing survival. Future studies should consider that: animal models are inadequate and cells used for animal models (mainly U87) are deeply different from patient GBM cells; GBM cells may become resistant to antiangiogenic therapy and some cells may be resistant to antiangiogenic therapy ab initio; and angiogenesis in the peritumor tissue has been poorly investigated. Therefore, the ideal target of angiogenesis is probably yet to be identified.
authors.affiliation: Catholic University School of Medicine, Rome, Italy.
authors.forename: Pasquale
authors.initials: P
authors.lastname: De Bonis
authors.forename: Giammaria
authors.initials: G
authors.lastname: Marziali
authors.forename: Vera
authors.initials: V
authors.lastname: Vigo
authors.forename: Simone
authors.initials: S
authors.lastname: Peraio
authors.forename: Angelo
authors.initials: A
authors.lastname: Pompucci
authors.forename: Carmelo
authors.initials: C
authors.lastname: Anile
authors.forename: Annunziato
authors.initials: A
authors.lastname: Mangiola
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D002986:Clinical Trials as Topic / Q000379:methods; D005910:Glioma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab